Management of chronic stable angina with an integrated approach of allopathic and ayurvedic medications
Phase 3
- Conditions
- Health Condition 1: I998- Other disorder of circulatory system
- Registration Number
- CTRI/2023/06/054147
- Lead Sponsor
- Shathyu Ayurveda Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients with symptoms of angina and documented CAD by CTCA with or without prior evidence of CAD will be eligible to be enrolled into the study.
Exclusion Criteria
Patients already listed or planning to undergo coronary angioplasty in the 6 month study period
Pregnant women
Seriously ill patients
Patients with psychiatric illnesses
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in anginal symptomsTimepoint: At 1st month, 3rd month and 6th month
- Secondary Outcome Measures
Name Time Method reduction in atherosclerotic plaque formationTimepoint: At 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by Ayurvedic compounds in combination with beta-blockers for chronic stable angina?
How does integrative therapy with allopathic and Ayurvedic medications compare to standard-of-care anti-anginal treatments in Phase III trials?
Which biomarkers correlate with improved outcomes in CTRI/2023/06/054147 integrative angina management?
What adverse events are associated with Shathyu Ayurveda's integrative approach for I998 circulatory disorders?
Are there other Ayurvedic compounds, such as Terminalia arjuna, being studied in combination with standard anti-anginal therapies for cardiovascular outcomes?